Download PDF
Horm Metab Res 2022; 54(04): 250-258
DOI: 10.1055/a-1796-9286
Original Article: Endocrine Research

Angiotensin(1–7) Improves Islet Function in Diabetes Through Reducing JNK/Caspase-3 Signaling

Jing Liu
1   Department of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, China
,
Xing Li
1   Department of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, China
,
Xiaoyan Wang
1   Department of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, China
,
Lina Peng
1   Department of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, China
,
Guoning Song
1   Department of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, China
,
Junhua He
1   Department of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

The aim of this study is to investigate whether Angiotensin (1–7), the physiological antagonist of Angiotensin II (AngII), has antidiabetic activity and the possible mechanism. Male Wistar rats were randomly divided into 3 groups: control group fed the normal diet, DM group fed high-fat diet and injected with STZ, and Angiotensin (1–7) group receiving injection of STZ followed by Angiotensin (1–7) treatment. Serum Ang II, fasting blood glucose, insulin, HOMA-IR, and HOMA-beta were determined in control, diabetes and Angiotensin (1–7) groups. The increased AngII and insulin resistance in diabetes group were accompanied by changes in islet histopathology. However, Angiotensin (1–7) improved the islet function and histopathology in diabetes without affecting the level of AngII. Western blot confirmed that Angiotensin (1–7) decreased the cleaved caspase 3 levels in pancreas of DM. The increased expression of JNK, Bax, and Bcl2 genes under diabetic conditions were partially reversed after Angiotensin (1–7) administration in pancreas. Immunofluorescence analysis showed that p-JNK was markedly increased in islet of DM rats, which was markedly alleviated after Angiotensin (1–7) treatment. Furthermore, Angiotensin (1–7) reversed high glucose(HG) induced mitochondrial apoptosis augments. Finally, Angiotensin (1–7) attenuated the apoptosis of INS-1 cells through reducing JNK activation in diabetes, which was blocked by anisomycin (a potent agonist of JNK). Our findings provide supporting evidence that Angiotensin (1–7) improved the islet beta-cells apoptosis by JNK-mediated mitochondrial dysfunction, which might be a novel target for the treatment and prevention of beta-cells dysfunction in DM.

Key words

angiotensin(1–7) - apoptosis - beta cells - diabetes mellitus type 2


Publication History

Received: 25 September 2021

Accepted after revision: 23 February 2022

Article published online:
12 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14,70469 Stuttgart, Germany

 

  • References

  • 1 Cho NH, Shaw JE, Karuranga S. et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-281
    CrossrefPubMedGoogle Scholar
  • 2 Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes 2017; 9: 320-324
    CrossrefPubMedGoogle Scholar
  • 3 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: P837-P853
    CrossrefPubMedGoogle Scholar
  • 4 Haataja L, Gurlo T, Huang CJ. et al. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 2008; 29: 303-316
    CrossrefPubMedGoogle Scholar
  • 5 Mandrup-Poulsen T. beta-cell apoptosis: stimuli and signaling. Diabetes 2001; 50: S58-S63
    CrossrefPubMedGoogle Scholar
  • 6 Leung PS. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. Diabet Med 2007; 24: 110-116
    CrossrefPubMedGoogle Scholar
  • 7 Yuan L, Li X, Li J. et al. Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol 2013; 50: 479-488
    CrossrefPubMedGoogle Scholar
  • 8 Duan Y, Prasad R, Feng D. et al. Bone marrow-derived cells restore functional integrity of the gut epithelial and vascular barriers in a model of diabetes and ACE2 deficiency. Circ Res 2019; 125: 969-988
    CrossrefPubMedGoogle Scholar
  • 9 Joyce-Tan SM, Zain SM, Abdul Sattar MZ. et al. Renin-angiotensin system gene variants and type 2 diabetes mellitus: influence of angiotensinogen. J Diabetes Res 2016; 2161376
    PubMedGoogle Scholar
  • 10 Santos SH, Andrade JM. Angiotensin 1-7: a peptide for preventing and treating metabolic syndrome. Peptides 2014; 59: 34-41
    CrossrefPubMedGoogle Scholar
  • 11 Santos RA. Angiotensin-(1-7). Hypertension 2014; 63: 1138-1147
    CrossrefPubMedGoogle Scholar
  • 12 Leung PS, Chappell MC. A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol 2003; 35: 838-846
    CrossrefPubMedGoogle Scholar
  • 13 Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007; 580: 31-37
    CrossrefPubMedGoogle Scholar
  • 14 Leung PS, Carlsson PO. Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 2005; 30: 293-298
    CrossrefPubMedGoogle Scholar
  • 15 Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-248
    CrossrefPubMedGoogle Scholar
  • 16 Yuan L, Lu CL, Wang Y. et al. Ang (1-7) protects islet endothelial cells from palmitate-induced apoptosis by AKT, eNOS, p38 MAPK, and JNK pathways. J Diabetes Res 2014; 391476
    PubMedGoogle Scholar
  • 17 Yuan L, Li Y, Li G. et al. Ang(1-7) treatment attenuates beta-cell dysfunction by improving pancreatic microcirculation in a rat model of Type 2 diabetes. J Endocrinol Invest 2013; 36: 931-937
    PubMedGoogle Scholar
  • 18 Akbarzadeh A, Norouzian D, Mehrabi MR. et al. Induction of diabetes by Streptozotocin in rats. Indian J Clin Biochem 2007; 22: 60-64
    CrossrefPubMedGoogle Scholar
  • 19 Salman ZK, Refaat R, Selima E. et al. The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats. Eur J Pharmacol 2013; 714: 448-455
    CrossrefPubMedGoogle Scholar
  • 20 Wang Y, Lau WB, Gao E. et al. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 2010; 298: E663-E670
    CrossrefPubMedGoogle Scholar
  • 21 Liu J, Meng Z, Gan L. et al. C1q/TNF-related protein 5 contributes to diabetic vascular endothelium dysfunction through promoting Nox-1 signaling. Redox Biol 2020; 34: 101476
    CrossrefPubMedGoogle Scholar
  • 22 Wang K, Gheblawi M, Oudit GY. Angiotensin converting enzyme 2: a double-edged sword. Circulation 2020; 142: 426-428
    CrossrefPubMedGoogle Scholar
  • 23 Walls AC, Park YJ, Tortorici MA. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181: 281-292 e286
    CrossrefPubMedGoogle Scholar
  • 24 Yan R, Zhang Y, Li Y. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444-1448
    CrossrefPubMedGoogle Scholar
  • 25 Patel VB, Zhong JC, Grant MB. et al. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res 2016; 118: 1313-1326
    CrossrefPubMedGoogle Scholar
  • 26 Vickers C, Hales P, Kaushik V. et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843
    CrossrefPubMedGoogle Scholar
  • 27 Bindom SM, Hans CP, Xia H. et al. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 2010; 59: 2540-2548
    CrossrefPubMedGoogle Scholar
  • 28 Dominici FP, Burghi V, Munoz MC. et al. Modulation of the action of insulin by angiotensin-(1-7). Clin Sci (Lond) 2014; 126: 613-630
    CrossrefPubMedGoogle Scholar
  • 29 Rein J, Bader M. Renin-angiotensin system in diabetes. Protein Pept Lett 2017; 24: 833-840
    CrossrefPubMedGoogle Scholar
  • 30 Sahr A, Wolke C, Maczewsky J. et al. The angiotensin-(1-7)/mas axis improves pancreatic beta-cell function in vitro and in vivo. Endocrinology 2016; 157: 4677-4690
    CrossrefPubMedGoogle Scholar
  • 31 Lelis DF, Freitas DF, Machado AS. et al. Angiotensin-(1-7), adipokines and inflammation. Metabolism 2019; 95: 36-45
    CrossrefPubMedGoogle Scholar
  • 32 Zhu Y, Liu Q, Zhou Z. et al. PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther 2017; 8: 240
    CrossrefPubMedGoogle Scholar
  • 33 Gao T, McKenna B, Li C. et al. Pdx1 maintains beta cell identity and function by repressing an alpha cell program. Cell Metab 2014; 19: 259-271
    CrossrefPubMedGoogle Scholar
  • 34 Li J, Zhu R, Liu Y. et al. Angiotensin-(1-7) improves islet function in a rat model of streptozotocin-induced diabetes mellitus by up-regulating the expression of Pdx1/Glut2. Endocr Metab Immune Disord Drug Targets 2021; 21: 156-162
    CrossrefPubMedGoogle Scholar
  • 35 Shu L, Sauter NS, Schulthess FT. et al. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 2008; 57: 645-653
    CrossrefPubMedGoogle Scholar
  • 36 Jeffrey KD, Alejandro EU, Luciani DS. et al. Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. Proc Natl Acad Sci U S A 2008; 105: 8452-8457
    CrossrefPubMedGoogle Scholar
  • 37 Butler AE, Janson J, Bonner-Weir S. et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110
    CrossrefPubMedGoogle Scholar
  • 38 Johnson JD, Luciani DS. Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Adv Exp Med Biol 2010; 654: 447-462
    CrossrefPubMedGoogle Scholar
  • 39 Thomas HE, McKenzie MD, Angstetra E. et al. Beta cell apoptosis in diabetes. Apoptosis 2009; 14: 1389-1404
    CrossrefPubMedGoogle Scholar
  • 40 Kikumoto Y, Sugiyama H, Inoue T. et al. Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice. Biochim Biophys Acta 2010; 1802: 240-246
    CrossrefPubMedGoogle Scholar
  • 41 Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-632
    CrossrefPubMedGoogle Scholar
  • 42 Chang KC, Hsu CC, Liu SH. et al. Cadmium induces apoptosis in pancreatic beta-cells through a mitochondria-dependent pathway: the role of oxidative stress-mediated c-Jun N-terminal kinase activation. PLoS One 2013; 8: e54374
    CrossrefPubMedGoogle Scholar
  • 43 Lee JS, Kim YR, Song IG. et al. Cyanidin-3-glucoside isolated from mulberry fruit protects pancreatic beta-cells against oxidative stress-induced apoptosis. International journal of molecular medicine 2015; 35: 405-412
    CrossrefPubMedGoogle Scholar
  • 44 Wang W, Wu RD, Chen P. et al. Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes. Diabetes Metab Res Rev 2020; 36: e3212
    CrossrefPubMedGoogle Scholar
  • 45 Wang C, Zou S, Cui Z. et al. Zerumbone protects INS-1 rat pancreatic beta cells from high glucose-induced apoptosis through generation of reactive oxygen species. Biochem Biophys Res Commun 2015; 460: 205-209
    CrossrefPubMedGoogle Scholar